Moody’s: 21st Century unaffected by missed interest payment

Moody's Investors Service said that 21st Century Oncology, Inc.'s failure to make the semi-annual interest payment under its senior notes due 2023 is a credit negative.

The company is within the 30-day cure period, which ends Dec. 1.

However, the missed interest payment does not currently affect 21st Century's Caa3 corporate family rating or negative outlook as they already incorporate high default risk.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.